Serum 2-hydroxyglutarate (2-HG), elevated in IDH1/2-mutant AML, distinguishes mutant from wild-type cases and serves as a diagnostic marker; persistently high 2-HG further predicts poorer survival, underscoring its role in risk stratification [200]. This evidence concerns the gene IDH1 and acute myeloid leukemia.